humani albumin octapharma 200 mg/ml raztopina za infundiranje
octapharma (ip) ltd., - albumin, humani - raztopina za infundiranje - albumin, humani 192 mg / 1 ml - albumin
humani albumin octapharma 50 mg/ml raztopina za infundiranje
octapharma (ip) ltd., - albumin, humani - raztopina za infundiranje - albumin, humani 48 mg / 1 ml - albumin
piperacilin/tazobaktam pharmaswiss 4 g/0,5 g prašek za raztopino za injiciranje ali infundiranje
pharmaswiss Česká republika s.r.o. - piperacilin; tazobaktam - prašek za raztopino za injiciranje/infundiranje - piperacilin 4 g / 1 viala tazobaktam0,5 g / 1 viala; tazobaktam 0,5 g / 1 viala - piperacilin in zaviralec laktamaz beta
vankomicin pharmaswiss 1000 mg prašek za raztopino za infundiranje
pharmaswiss Česká republika s.r.o. - vankomicin - prašek za raztopino za infundiranje - vankomicin 1000 mg / 1 viala - vankomicin
pemetreksed pharmaswiss 500 mg prašek za koncentrat za raztopino za infundiranje
pharmaswiss Česká republika s.r.o. - pemetreksed - prašek za koncentrat za raztopino za infundiranje - pemetreksed 500 mg / 1 viala - pemetreksed
pemetreksed pharmaswiss 100 mg prašek za koncentrat za raztopino za infundiranje
pharmaswiss Česká republika s.r.o. - pemetreksed - prašek za koncentrat za raztopino za infundiranje - pemetreksed 100 mg / 1 viala - pemetreksed
clopidogrel taw pharma (previously clopidogrel mylan)
taw pharma (ireland) limited - klopidogrel hidroklorid - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antitrombotična sredstva - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:, - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). , - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.
pioglitazone teva pharma
teva pharma b.v. - pioglitazon hidroklorid - diabetes mellitus, tip 2 - zdravila, ki se uporabljajo pri diabetesu - pioglitazone is indicated in the treatment of type-2 diabetes mellitus as monotherapy: , in adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance. , pioglitazone is also indicated for combination with insulin in type 2 diabetes mellitus adult patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance. po začetku terapije z pioglitazone, bolnike je treba pregledati in po 3 do 6 mesecev, da oceni ustreznost odziva na zdravljenje (e. zmanjšanje hba1c). pri bolnikih, ki ne kažejo ustrezen odgovor, pioglitazone, je treba prekiniti,. v luči možnih tveganj z dolgotrajna terapija, predpisovalce morajo potrditi na kasnejše redne preglede, da je korist pioglitazone je ohranjena.
bortezomib pharmaswiss 3,5 mg prašek za raztopino za injiciranje
pharmaswiss Česká republika s.r.o. - bortezomib - prašek za raztopino za injiciranje - bortezomib 3,5 mg / 1 viala - bortezomib
zoledronic acid teva pharma
teva b.v. - zoledronska kislina - osteoporosis; osteitis deformans; osteoporosis, postmenopausal - zdravila za zdravljenje bolezni kosti - treatment of osteoporosis: , in post-menopausal women;, in men; , at increased risk of fracture including those with a recent low-trauma hip fracture. treatment of osteoporosis associated with long-term systemic glucocorticoid therapy: , in post-menopausal women;, in men; , at increased risk of fracture. zdravljenje paget je bolezen kosti v odrasli.